Lattice Biologics Ltd.
LBLTF
$0.00
$0.000.00%
OTC PK
| 06/30/2021 | 03/31/2021 | 12/31/2020 | 09/30/2020 | 06/30/2020 | |
|---|---|---|---|---|---|
| Revenue | -- | 287.70K | 474.60K | 795.80K | 504.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 287.70K | 474.60K | 795.80K | 504.20K |
| Cost of Revenue | -- | 241.70K | 203.90K | 466.80K | 342.90K |
| Gross Profit | -- | 46.00K | 270.70K | 329.00K | 161.40K |
| SG&A Expenses | 25.80K | 333.90K | 323.50K | 111.20K | 336.80K |
| Depreciation & Amortization | -- | 101.50K | 64.00K | 179.70K | 51.80K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.80K | 677.10K | 591.40K | 757.60K | 731.50K |
| Operating Income | -25.80K | -389.40K | -116.80K | 38.10K | -227.30K |
| Income Before Tax | -25.80K | -389.40K | -269.10K | -239.30K | -319.70K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.80K | -389.40K | -269.10K | -239.30K | -319.70K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.80K | -389.40K | -269.10K | -239.30K | -319.70K |
| EBIT | -25.80K | -389.40K | -116.80K | 38.10K | -227.30K |
| EBITDA | 43.10K | -353.80K | -81.20K | 182.40K | -198.80K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 128.22M | 128.22M | 128.22M | 123.87M | 99.54M |
| Average Diluted Shares Outstanding | 128.22M | 128.22M | 128.22M | 123.87M | 99.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |